Lai L W, Lien Y H
Department of Medicine, Sections of Endocrinology and Nephrology, University of Arizona Health Sciences Center, Tucson, Ariz. 95724, USA.
Exp Nephrol. 1999 Jan-Feb;7(1):11-4. doi: 10.1159/000020578.
BACKGROUND/AIMS: Most of the current expression vector based gene therapy protocols fail to achieve clinically significant transgene expression required for treating genetic diseases. Homologous recombination, initially considered to be of limited use for gene therapy because of its low frequency in mammalian cells, has recently emerged as a potential strategy for developing gene therapy.
Six recent studies of homologous recombination in mammalian cells are reviewed. Different approaches have been used in these studies including RNA/DNA chimeric oligonucleotides, small or large homologous DNA fragments, or adeno-associated viral vectors.
Most of these studies show a reasonable frequency of homologous recombination which warrants further in vivo testing.
Homologous recombination based gene therapy has the potential to develop into a powerful therapeutic modality for genetic diseases. It can offer permanent expression and normal regulation of corrected genes in appropriate cells or organs and probably can be used for treating dominantly inherited diseases such as polycystic kidney disease.
背景/目的:目前大多数基于表达载体的基因治疗方案未能实现治疗遗传性疾病所需的具有临床意义的转基因表达。同源重组最初因在哺乳动物细胞中频率较低而被认为在基因治疗中用途有限,近来已成为开发基因治疗的一种潜在策略。
综述了最近六项关于哺乳动物细胞同源重组的研究。这些研究采用了不同方法,包括RNA/DNA嵌合寡核苷酸、小或大的同源DNA片段,或腺相关病毒载体。
这些研究大多显示出合理的同源重组频率,值得进一步进行体内试验。
基于同源重组的基因治疗有潜力发展成为一种治疗遗传性疾病的强大治疗方式。它可以在适当的细胞或器官中实现校正基因的永久表达和正常调控,并且可能可用于治疗诸如多囊肾病等显性遗传性疾病。